Three Nights Without Sleep and a New Business Plan Every Hour: Managing Acute Mania in a 44-Year-Old With Bipolar I Disorder, From the Antimanic Evidence to the Maintenance Choice
[Student Name]
University of Phoenix
PMH/504: Psychiatric Management Of Adult And Geriatric Patients
Week 3 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Mr. R., a 44-year-old restaurant owner with bipolar I disorder, stopped lithium two months ago because he "felt fine." For the past week his nights have lasted two or three hours at most, talked rapidly, spent $18,000 on equipment for a second restaurant he has not discussed with his partner and been irritable when interrupted. His wife brought him in. He denies hallucinations but believes he is "destined to run a restaurant empire." This paper describes acute management and planning for maintenance.
Safety and Setting
The first question is where he can be safely treated. He is not violent or suicidal, is eating and has insight that he "might be a bit high," and his wife can supervise. However, his judgment is impaired and financial harm is ongoing. I discuss day hospital or intensive outpatient treatment with daily contact; hospitalization would be needed if he becomes dangerous, psychotic beyond grandiosity or unable to care for himself.
Choosing Acute Treatment
Cipriani et al. (2011) conducted a network meta-analysis of antimanic drugs and found that antipsychotics were more effective than mood stabilizers overall, with haloperidol, risperidone and olanzapine among the most effective, and that olanzapine, risperidone and quetiapine offered a favorable balance of efficacy and acceptability. The CANMAT/ISBD guideline recommends lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone and cariprazine as first-line monotherapies for acute mania, and combinations of lithium or divalproex with an antipsychotic (Yatham et al., 2018).
The fastest drug for this week is not always the best drug for the next ten years, so both decisions are made together.
The Decision
Because Mr. R. responded to lithium previously and needs rapid control, I restart lithium, titrating to a level of 0.8 to 1.0 mmol/L, and add quetiapine at night for rapid control of sleep and agitation. His kidney and thyroid function are normal on recent labs. The combination follows guideline recommendations (Yatham et al., 2018).
Monitoring
Lithium levels at five days and after each dose change; kidney function, thyroid function and calcium at baseline and every three to six months; weight and metabolic labs for quetiapine. Signs of lithium toxicity, such as tremor, vomiting, diarrhea, confusion or unsteadiness, are explained to him and his wife.
Protecting Finances and Relationships
With his consent, his wife will hold the credit cards temporarily, and major purchases will wait until he is well. We discuss this plan while he has partial insight.
The Transition to Maintenance
After the episode resolves, the question becomes long-term prevention. The CANMAT/ISBD guideline recommends lithium as a first-line maintenance treatment with evidence for preventing both manic and depressive episodes and for reducing suicide risk, with quetiapine also first-line (Yatham et al., 2018). Mr. R. will continue lithium; quetiapine may be tapered once he is stable for several months, or continued if needed.
Why He Stopped Lithium
Stopping medication because one feels well is common. I will use motivational interviewing when he is euthymic to explore his reasons, his experience of this episode and his goals, which may strengthen adherence more than warnings now.
Engaging Him While Manic
People in mania often reject the idea that they are ill. Rather than arguing, I focus on shared goals he endorses, such as protecting the restaurant he has built and his marriage, and on sleep, which he agrees has become a problem. Framing medication as a way to get sleep back makes it more acceptable.
Why Lithium Rather Than Valproate
Lithium has the strongest evidence for long-term prevention of both mania and depression and a specific benefit in reducing suicide, which guides the CANMAT/ISBD first-line recommendation (Yatham et al., 2018). Valproate is effective for acute mania but has less evidence for depression and suicide prevention. Mr. R.'s prior response to lithium favors it.
Returning to Work
His restaurant needs him, but decisions made in mania can harm it. With his partner, we agree that he will step back from financial decisions for four weeks while continuing daily operations he enjoys, preserving his role without risk.
Motivational Work Later
When he is euthymic, motivational interviewing can explore his ambivalence about lithium in his own terms, drawing out his reasons to stay well rather than lecturing him, an approach grounded in evoking the person's own motivation (Miller & Rose, 2009).
Psychoeducation
Family-focused psychoeducation about early warning signs, sleep regularity and substance avoidance reduces relapse. His wife noticed decreased sleep two weeks before the episode; this becomes an agreed signal to call.
Lithium and Pregnancy Planning
His wife is not planning pregnancy, but in women, lithium requires specific counseling about pregnancy; I note this for completeness in his family education.
Substance Use
Alcohol and cannabis can trigger or worsen mood episodes. Mr. R. drinks more when manic. We agree on abstinence during recovery and revisit it at follow-up.
Follow-Up
Visits twice weekly during the acute phase, then weekly, with lithium levels guiding dose changes.
Sleep First
Restoring sleep is both a treatment target and an early marker of response. Quetiapine at night, a dark and quiet bedroom and limiting stimulation in the evening help. Improvement in sleep usually precedes improvement in other manic symptoms.
Monitoring for Depression After Mania
Mood often swings toward depression after a manic episode resolves. His wife and I will watch for low mood and withdrawal in the following weeks, since the transition is a high-risk period for suicide.
Documentation
The note records the symptoms, the safety assessment, the setting decision, the medication rationale and the agreed plan for finances.
Why Not Hospitalize Now
Hospitalization protects but disrupts work and family and may feel coercive. Because Mr. R. accepts treatment, has supervision at home and poses no immediate danger, a less restrictive setting is appropriate, with clear criteria for escalation written into the plan.
Lithium Level Targets
For acute mania, many guidelines target lithium levels around 0.8 to 1.2 mmol/L, while maintenance often aims for 0.6 to 0.8 mmol/L, adjusted to response and tolerability. Explaining the reason for frequent early level checks helps him accept the blood draws.
His Partner
His restaurant partner is informed, with Mr. R.'s consent, of the temporary pause on financial decisions and of whom to call if concerned, protecting the business relationship during recovery and so he has a clear contact if the plan slips.
Legal and Ethical Limits
If his judgment worsened to the point of danger, involuntary treatment laws would apply; for now, voluntary care with his agreement is both ethical and effective.
Conclusion
Mr. R.'s manic episode after stopping lithium required a safety assessment, a setting that protects him and his finances and acute treatment chosen from network meta-analytic evidence and the CANMAT/ISBD guideline. Restarting lithium with quetiapine controls the episode while laying the foundation for lithium maintenance, supported by psychoeducation and later work on adherence.
References
Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., Purgato, M., Spineli, L. M., Goodwin, G. M., & Geddes, J. R. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. The Lancet, 378(9799), 1306-1315. https://doi.org/10.1016/S0140-6736(11)60873-8
Miller, W. R., & Rose, G. S. (2009). Toward a theory of motivational interviewing. American Psychologist, 64(6), 527-537. https://doi.org/10.1037/a0016830
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., Alda, M., MacQueen, G., Milev, R. V., Ravindran, A., O'Donovan, C., McIntosh, D., Lam, R. W., Vazquez, G., Kapczinski, F., . . . Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97-170. https://doi.org/10.1111/bdi.12609
How this PMH 504 Week 3 example is structured
The PMH/504 Week 3 work usually covers bipolar disorder across its phases. This paper moves from the acute phase, where safety and speed matter most, to maintenance, where prevention and adherence matter most, using the same guideline for both. Students search this week as PMH 504 Week 3, PMH504 Wk 3 or PMH/504 Wk 3; all three are the same assignment.
PMH/504 Week 3 questions, answered
What does PMH/504 Week 3 usually ask for?
Many sections ask students to manage bipolar disorder across phases, including acute mania, bipolar depression and maintenance.
Which drugs work best for acute mania?
A network meta-analysis found that antipsychotics such as haloperidol, risperidone and olanzapine were among the most effective, with olanzapine, risperidone and quetiapine offering a good balance of efficacy and acceptability; lithium and valproate are also first-line.
What is first-line maintenance for bipolar I disorder?
Guidelines favor lithium as a first-line maintenance agent, with quetiapine, lamotrigine for depression-predominant courses and other options depending on the patient's history.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.